Prof Joy Ho is Professor, Alan Ng Chair in Haematology, University of Sydney, and Head of Department & Director of Research at the Institute of Haematology, Royal Prince Alfred Hospital (RPAH), Sydney. She is Clinical Lead, Haematology CAR-T Program and Head of the Myeloma Unit in RPAH. She is the Founding Director of Sydney Blood Cancer Research Institute. Her research achievements include stewardship of national clinical trials, and has brought multiple clinical trials on novel CAR-T, myeloma and lymphoma therapies to RPAH and Australia. She is also head of the RPA Thalassemia Unit which performed the first gene therapy trial in Australia. She was President of the Haematology Society of Australia and New Zealand (HSANZ) in 2013-15. She is Foundation Member and was Deputy Chair of the Medical and Scientific Advisory group of Myeloma Australia, and member of the International Myeloma Working Group.

She was elected to the Board of the International Myeloma Society in 2019, and has served on the Education Committee since 2016. She served on the Australasian Leukaemia & Lymphoma Group Scientific and Executive Committees, and chaired the Laboratory Science Committee in 2005-11. In 2017-2021, she was appointed to the Pharmaceutical Benefits Advisory Committee by the Australian Government. For the American Society of Hematology (ASH), she is an invited member of the International Members’ Committee since 2016 and was appointed Vice Chair in 2021, and Chair of Metrics since 2018. Awards received include the Carl de Gruchy Oratorship of the HSANZ in 2022, Albert Baikie Memorial Medal, Kanematsu Memorial Award, Arnott Fellowship in Cancer Research, New York Academy of Sciences Fellowship and Oxford Nuffield Medical Fellowship. She is author of multiple publications on myeloma, lymphoma, cellular immunotherapy and haemoglobinopathies.